NPT088 targets amyloid in vitro and in animal models of Alzheimer's disease (AD), reducing β-amyloid plaque and tau aggregate loads in a mouse disease model (Levenson et al., 2016). This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.